Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18423386 | 0.81 | ROCK2 (0.49) | ROCK2ARHGDIAROCK1MAPTSIGMAR1 | |
| SCHEMBL18423389 | 0.81 | ROCK2 (0.49) | ROCK2ARHGDIAROCK1MAPTSIGMAR1 | |
| SCHEMBL5833037 | 0.80 | MAPT (0.50) | ROCK2ARHGDIAROCK1MAPTSIGMAR1 | |
| SCHEMBL4128561 | 0.80 | KDM1A (0.50) | SIGMAR1 | |
| SCHEMBL5833034 | 0.76 | ROCK2 (0.46) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL1976246 | 0.76 | ROCK2 (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL4190627 | 0.76 | ROCK2 (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL4966861 | 0.76 | MAPT (0.50) | ROCK2ARHGDIAROCK1MAPTSIGMAR1 | |
| SCHEMBL4966858 | 0.76 | ROCK2 (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL1976244 | 0.76 | ROCK2 (0.44) | ROCK2ARHGDIAROCK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808445-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170027916-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | US | disclosed |
| EP-1317430-B1 | (2-AZABICYCLO [2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2005-05-18 | — | — | EP | disclosed |
| EP-1317430-A1 | (2-AZABICYCLO 2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GmbH (DE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022578-A1 | (2-AZABICYCLO[2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027916-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | ROCK2 1967/4885ARHGDIA 1662/4885ROCK1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.